Simba Gill, Evelo Biosciences CEO
October 17, 2023 11:21 AM EDT
R&D

Evelo dealt an­oth­er blow with a PhII fail, plans for strate­gic al­ter­na­tives

Anna Brown

News Reporter

Evelo Bio­sciences is ex­plor­ing strate­gic al­ter­na­tives for its mid-stage pso­ri­a­sis treat­ment af­ter it re­port­ed that an­oth­er pso­ri­a­sis drug failed a Phase II clin­i­cal tri­al. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times